세계의 정맥주사(IV) 용액 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Intravenous Solutions Market is presumed to reach the market size of nearly USD 35.49 Billion by 2032 from USD 17.99 Billion in 2023 with a CAGR of 7.84% under the study period 2024-2032.

Intravenous (IV) solutions are sterile fluids administered directly into a patient's veins to deliver medications, nutrients, or fluids for therapeutic purposes. These solutions are essential in medical settings for patients who cannot consume liquids orally or require immediate absorption of medications. Intravenous solutions typically contain a balanced combination of water, electrolytes (sodium, potassium, and chloride), and sometimes additional substances like glucose or medications. They play an integral role in maintaining hydration & electrolyte balance and supporting vital functions in patients undergoing surgery, recovering from illnesses, or managing chronic conditions. IV solutions are available in various types and compositions, which are customized to meet specific medical needs and treatment requirements, ensuring precise delivery and therapeutic efficacy.

MARKET DYNAMICS

The increasing prevalence of chronic diseases, surgeries, and medical emergencies necessitates reliable intravenous solutions for fluid replacement, medication delivery, and nutritional support. Advances in medical technology, such as improved infusion pumps and catheter designs, enhance the safety and efficiency of IV administration, contributing to better patient outcomes and reduced hospital stays. Demographic trends such as aging populations and the rising incidence of complex diseases drive market growth. The demand for intravenous solutions is further bolstered by the expansion of outpatient care and home healthcare settings, where patients require convenient and portable infusion options for continuous therapy management.

Technological innovations in IV therapy, including smart IV pumps and integrated electronic medical records, improve treatment precision and patient monitoring, promoting adoption across healthcare facilities. Moreover, regulatory initiatives to enhance patient safety and quality standards create opportunities for compliant intravenous solutions manufacturers to expand their market presence and innovate new products. Strategic collaborations among pharmaceutical companies, medical device manufacturers, and healthcare providers facilitate product development and distribution, enhancing market competitiveness and scalability globally. However, stringent regulatory requirements for product approval and pricing dynamics in healthcare systems hampers market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Intravenous Solutions. The growth and trends of Intravenous Solutions industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Intravenous Solutions market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition

By Composition

• Carbohydrates
• Vitamins & Minerals
• Single-Dose Amino Acids
• Parenteral Lipid Emulsion
• Other Compositions

By Age Group

• Pediatric
• Adult
• Geriatric

By Application

• Nutritional Support
• Blood Transfusion
• Fluid & Electrolyte Balance
• Other Applications

By End-User

• Hospitals And Clinics
• Ambulatory Surgery Centers
• Home Care Setting

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Solutions market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Solutions market include Ajinomoto Co Inc., Amanta Healthcare, Axa Parenterals Ltd, B.Braun Melsungen AG, Baxter International Inc., Fresenius Kabi USA LLC, Grifols S.A., ICU Medical Inc, JW Life Science, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. INTRAVENOUS SOLUTIONS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Composition
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Application
  • 3.7.5 Market Attractiveness Analysis By End-User
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Total Parenteral Nutrition Historic and Forecast Sales By Regions
• 5.4. Peripheral Parenteral Nutrition Historic and Forecast Sales By Regions

6. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY COMPOSITION

• 6.1. Overview By Composition
• 6.2. Historical and Forecast Data Analysis By Composition
• 6.3. Carbohydrates Historic and Forecast Sales By Regions
• 6.4. Vitamins & Minerals Historic and Forecast Sales By Regions
• 6.5. Single-Dose Amino Acids Historic and Forecast Sales By Regions
• 6.6. Parenteral Lipid Emulsion Historic and Forecast Sales By Regions
• 6.7. Other Compositions Historic and Forecast Sales By Regions

7. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data Analysis By Age Group
• 7.3. Pediatric Historic and Forecast Sales By Regions
• 7.4. Adult Historic and Forecast Sales By Regions
• 7.5. Geriatric Historic and Forecast Sales By Regions

8. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY APPLICATION

• 8.1. Overview By Application
• 8.2. Historical and Forecast Data Analysis By Application
• 8.3. Nutritional Support Historic and Forecast Sales By Regions
• 8.4. Blood Transfusion Historic and Forecast Sales By Regions
• 8.5. Fluid & Electrolyte Balance Historic and Forecast Sales By Regions
• 8.6. Other Applications Historic and Forecast Sales By Regions

9. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY END-USER

• 9.1. Overview By End-User
• 9.2. Historical and Forecast Data Analysis By End-User
• 9.3. Hospitals And Clinics Historic and Forecast Sales By Regions
• 9.4. Ambulatory Surgery Centers Historic and Forecast Sales By Regions
• 9.5. Home Care Setting Historic and Forecast Sales By Regions

10. GLOBAL INTRAVENOUS SOLUTIONS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE INTRAVENOUS SOLUTIONS COMPANIES

• 11.1. Intravenous Solutions Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF INTRAVENOUS SOLUTIONS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Ajinomoto Co Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Amanta Healthcare
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Axa Parenterals Ltd
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. B.Braun Melsungen AG
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Baxter International Inc.
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Fresenius Kabi USA LLC
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Grifols S.A.
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. ICU Medical Inc
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. JW Life Science
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Otsuka Pharmaceutical Co. Ltd
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. Pfizer Inc
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies